# Doug Levinson

> Doug Levinson is the co-founder and CEO of Fount Bio, a Somerville, Massachusetts life science company building Flī-HA, a platform to deliver long-lasting hyaluronic acid into skin through topical application rather than injection. A serial life-sciences entrepreneur with a Harvard PhD in genetics, Levinson has spent roughly 25 years founding and running companies across diagnostics, aesthetics, and drug delivery, including Cytrellis Biosystems, T2 Biosystems, and YourBio Health, after early stints at Millennium Pharmaceuticals and TransForm Pharmaceuticals and a partner role at Flagship Ventures.

- **Role:** Co-Founder and CEO at Fount Bio, Inc.
- **Organizations:** Fount Bio, Inc., Cytrellis Biosystems, T2 Biosystems, YourBio Health, Flagship Ventures (Flagship Pioneering), TransForm Pharmaceuticals, Millennium Pharmaceuticals
- **Nationality:** American
- **Education:** Ph.D. in Genetics, Harvard University, B.S. in Molecular Biology, cum laude, University of Massachusetts
- **Known for:** Co-founded and leads Fount Bio, developer of the Flī-HA (functional ligand hyaluronic acid) topical delivery platform., Founded and served as CEO of Cytrellis Biosystems, which developed an FDA-cleared proprietary system for aesthetic dermatology., Founded T2 Biosystems, a commercial-stage nanotechnology diagnostics company (Nasdaq: TTOO).

## Career timeline

- **1990s** — Founding scientific team member at Millennium Pharmaceuticals; built its Immunology/Inflammation program to ~170 researchers over seven years.
- **2000** — Joined TransForm Pharmaceuticals as part of the scientific founding team, working with MIT professors Bob Langer and Michael Cima.
- **2005** — TransForm Pharmaceuticals acquired by Johnson & Johnson for $230 million.
- **2006** — Joined Flagship Ventures as a partner on the life-sciences team.
- **2018** — Co-founded Fount Bio with bioengineer Samir Mitragotri.
- **2021** — Fount Bio closed a Series A financing led by Morningside Ventures to advance the Flī-HA platform toward clinical proof of concept.

## Achievements

- Co-founded and leads Fount Bio, developer of the Flī-HA (functional ligand hyaluronic acid) topical delivery platform.
- Founded and served as CEO of Cytrellis Biosystems, which developed an FDA-cleared proprietary system for aesthetic dermatology.
- Founded T2 Biosystems, a commercial-stage nanotechnology diagnostics company (Nasdaq: TTOO).
- Founded YourBio Health, developer of simple blood-collection and diagnostics devices.
- Member of the founding scientific team at TransForm Pharmaceuticals, acquired by Johnson & Johnson for $230 million.
- Built Millennium Pharmaceuticals' Immunology/Inflammation research effort into its largest program, with roughly 170 researchers.

## Latest updates

- **2021-07** — Fount Bio closed its Series A financing led by Morningside Ventures to advance the Flī-HA platform to clinical proof of concept.
- **2022-02** — Fount Bio published updated leadership and team profiles, with Levinson listed as Founder, CEO and Director.

## Links

- Website: https://www.fountbio.com
- LinkedIn: https://www.linkedin.com/in/doug-levinson-a691832/

---

Profile page: https://yespress.io/doug-levinson
Published by YesPress — https://yespress.io
Last updated: 2026-07-17